Skip to content

A randomised controlled clinical trial study of electric field-coupled negative pressure integrated therapy to promote the repair of chronic difficult-to-heal wounds of the lower limb

A randomised controlled clinical trial study of electric field-coupled negative pressure integrated therapy to promote the repair of chronic difficult-to-heal wounds of the lower limb

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077860
Enrollment
Unknown
Registered
2023-11-22
Start date
2023-11-22
Completion date
Unknown
Last updated
2024-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic wounds or ulcers of the lower extremities

Interventions

Control group (negative pressure therapy group):Perform wound debridement and installation of negative pressure therapy devices according to standard procedures
Pilot group (electric field coupled negative pressure integrated treatment group):Perform wound debridement and installation of electric field coupled negative pressure integrated treatment device acc

Sponsors

the First Affiliated Hospital of Army Medical Universiy,PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Voluntary participation in the study and signing the informed consent form; 2) Age between 60 and 80 years old; (3) Patients diagnosed with diabetic lower limb ulcers (LEDUS) or lower limb arterial ulcers (LEAUS) with a disease duration of more than 4 weeks and no tendency to heal spontaneously; (4) Patients with a wound area of =6cm2 and =25cm2, with no obvious necrotic tissue remaining and no deep tendons, nerves, blood vessels or bone exposed; (5) The glycosylated haemoglobin (HbA1c) of the patients was controlled within 10% at the time of enrolment; (6) The patient's ankle-brachial index (ABI) is more than 0.7.

Exclusion criteria

Exclusion criteria: 1) Patients with definite malignant tumours, AIDS or autoimmune diseases; 2) Patients with definite severe cardiac, pulmonary, haematological or neurological diseases; 3) Patients with haemoglobin (HB) <90g/L; 4) Patients with albumin <25g/L; 5) Patients with severe peritraumatic infections; 6) Patients with combined sepsis or systemic multi-organ failure; 7) Those who have participated and are participating in other clinical studies within 3 months; 8) those with poor compliance and difficulty in completing the trial

Design outcomes

Primary

MeasureTime frame
Percentage of wounds healed at day 14 post-treatment;

Secondary

MeasureTime frame
Wound granulation coverage;Degree of inflammatory response at the trabecular margin;Rate of wound healing;Wound healing rate;

Countries

CHINA

Contacts

Public ContactZhang Jiaping

the First Affiliated Hospital of Army Medical Universiy,PLA

1980475546@qq.com+86 134 5296 4445

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026